Cargando…

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xuanzhao, Li, Zeyan, Liang, Meihua, Zhang, Ziyang, Zhu, Di, Lin, Biyun, Zhou, Renyu, Lu, Yuanzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311827/ https://www.ncbi.nlm.nih.gov/pubmed/37391802 http://dx.doi.org/10.1186/s12957-023-03078-7

Ejemplares similares

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer
por: Jia, Zhenya, et al.
Publicado: (2018)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy
por: Jiang, Ting, et al.
Publicado: (2023)

Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
por: Oualla, Karima, et al.
Publicado: (2020)

Identification of autophagy‐related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA)
por: Cao, Rui, et al.
Publicado: (2021)

Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
por: Khadela, Avinash, et al.
Publicado: (2022)

Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential
por: Das, Kaushik, et al.
Publicado: (2023)

Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer
por: Zhou, Renyu, et al.
Publicado: (2022)

Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics
por: Kommineni, Nagavendra, et al.
Publicado: (2022)

Autonomic Neural Circuit and Intervention for Comorbidity Anxiety and Cardiovascular Disease
por: Chen, Xuanzhao, et al.
Publicado: (2022)

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2015)

DDIT3 Expression in Liposarcoma Development
por: Kåbjörn Gustafsson, Christina, et al.
Publicado: (2014)

Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment
por: Winter, Marie, et al.
Publicado: (2021)

Identification of a Small Molecule Inhibitor of Hyaluronan Synthesis, DDIT, Targeting Breast Cancer Cells
por: Karalis, Theodoros, et al.
Publicado: (2022)

The FUS-DDIT3 Interactome in Myxoid Liposarcoma()
por: Yu, Jamie S.E., et al.
Publicado: (2019)

DDIT4 Novel Mutations in Pancreatic Cancer
por: Ding, Fadian, et al.
Publicado: (2021)

DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2
por: Bento, Christoffer, et al.
Publicado: (2009)

A comprehensive analysis of the expression and regulation network of lymphocyte-specific protein tyrosine kinase in breast cancer
por: Meng, Yuhua, et al.
Publicado: (2021)

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
por: Deng, Jiaojiao, et al.
Publicado: (2021)

Identification of FOXM1 as a specific marker for triple-negative breast cancer
por: Tan, Yanli, et al.
Publicado: (2018)

DDIT3 antagonizes innate immune response to promote bovine alphaherpesvirus 1 replication via the DDIT3-SQSTM1-STING pathway
por: Wang, Song, et al.
Publicado: (2022)

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer
por: Soady, Kelly J, et al.
Publicado: (2015)

β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer
por: Yin, Hsin-Ling, et al.
Publicado: (2016)

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
por: Pan, Yunbao, et al.
Publicado: (2017)

Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2018)

Chemotherapeutic Stress Influences Epithelial–Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer
por: Li, Xiao, et al.
Publicado: (2020)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
por: Chen, Bo, et al.
Publicado: (2018)

Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging
por: Phillips, Leo, et al.
Publicado: (2019)

Methylation status of DDIT3 gene in Chronic Myeloid Leukemia
por: Wang, Ya-li, et al.
Publicado: (2010)

DDIT4 overexpression associates with poor prognosis in lung adenocarcinoma
por: Song, Li, et al.
Publicado: (2021)

Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer
por: Gao, Yan, et al.
Publicado: (2022)

Long Non-coding Antisense RNA DDIT4-AS1 Regulates Meningitic Escherichia coli-Induced Neuroinflammation by Promoting DDIT4 mRNA Stability
por: Yang, Bo, et al.
Publicado: (2022)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies
por: Pinto, Joseph A., et al.
Publicado: (2017)

Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer
por: Sun, Yuanhong, et al.
Publicado: (2019)

Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer
por: Roseweir, Antonia K., et al.
Publicado: (2017)

ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer
por: Panigoro, Sonar Soni, et al.
Publicado: (2020)

A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer
por: Turkistani, Safaa, et al.
Publicado: (2021)

Triple negative breast cancer – prognostic factors and survival
por: Ovcaricek, Tanja, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kfeumktendgq0a8h36dssravgj